BTV100 Low dose

Phase 2Small molecule

BBioTheraVision, Inc.

BTV100 Low dose is one of 37 small molecule programs targeting Eye Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eye DiseaseActive, not recruiting

Eye DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

200 competitors in Eye Disease

#DrugCompanyPhaseTrials

Neoral

Novartis

Phase 3

2 2

Alphagan

AbbVie

Phase 3

2 3

Chantix

Pfizer

Phase 3

2 4

Bayer Aspirin

Bayer

Phase 3

1 5

Zovirax

BBp Consulting, Inc

Phase 3

2 6

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 7

CF101

CCan-Fite BioPharma

Phase 3

1 8

Carboxymethylcellulose

AbbVie

Phase 3

4 9

Cenegermin

DDompé Farmaceutici S.p.A

Phase 3

1 10

Csa

ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Eye Disease1 trial

Evaluation of BTV100 in Subjects With Dry Eye Disease

Recruiting·BBioTheraVision, Inc.·Phase 2·NCT06543303·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BTV100 Low dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BTV100 Low dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BTV100 Low dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioTheraVision, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBioTheraVision, Inc.

BTV100 Low dose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Eye Disease1 trial

References

Drug Info

Quick Facts

Related News